<DOC>
	<DOCNO>NCT01683058</DOCNO>
	<brief_summary>The phase 3 Trial 31-12-291 part aripiprazole IM depot clinical development program design demonstrate efficacy safety aripiprazole IM depot treatment adult experience acute relapse schizophrenia . Subjects receive treatment 12-week double-blind acute treatment phase . The current trial ( 31-12-297 ) allow subject complete Trial 291 enter open label trial investigator 's discretion , additional safety tolerability data collect .</brief_summary>
	<brief_title>Open-label , Extension Study Aripiprazole Intramuscular Depot ( OPC-14597 , Lu AF41155 ) Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Male female subject 18 66 year age , inclusive , time informed consent . Subjects able provide write informed consent ( require IRB/IEC ) prior initiation protocolrequired procedure . Ability , opinion investigator , understand nature trial follow protocol requirement , include prescribed dosage regimen , tablet ingestion , discontinuation prohibit concomitant medication , reliably rat assessment scale . Subjects meet completion criterion 3112291 registrational trial acute treatment adult schizophrenia Subjects , investigator 's judgment , require chronic treatment antipsychotic medication would benefit extended treatment IM depot formulation . Outpatient status Week 12 Trial 291 , exception subject eligible enter Trial 297 due positive interim analysis . Sexually active male childbearing potential agree practice 2 different method birth control remain abstinent trial 180 day last dose trial medication . Sexually active Women Childbearing Potential agree practice 2 different method birth control remain abstinent trial 150 day last dose trial medication . Females breastfeed and/or positive pregnancy test result prior receive IMP trial . Subjects experience acute depressive symptom within past 30 day , accord investigator 's opinion , require treatment antidepressant . Subjects anticipate need CYP2D6 CYP3A4 inhibitor CYP3A4 inducer course trial . Subjects significant risk violent behavior ; represent risk commit suicide ; clinical judgment investigator present serious risk suicide . Subjects require antipsychotic ( ) aripiprazole IM depot completion Trial 291 . Subjects likely require prohibit concomitant therapy trial Laboratory test ECG result exclusionary Any subject , opinion investigator medical monitor , participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>